Synamatix Partners with PREMAS Biotech to Deliver Next-Generation Sequencing and Bioinformatics Services to India
Synamatix announced a partnership agreement with India-based PREMAS Biotech. In this agreement PREMAS will act as Synamatix's representative in India, Bangladesh and Sri Lanka.

Synamatix Partners With GeneWorks to Deliver Next-generation Sequencing and Bioinformatics Support for Key Research Institutions in Asia and Australia
Synamatix today announced its partnership with GeneWorks for the provision of sequencing and bioinformatics research support to key customers within Asia and Australia. The two companies will provide genome institutes in Asia with an extensive and comprehensive range of sequencing and bioinformatics solutions to support and enhance research.

Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lowe
Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science research and discovery solutions, today announced that its technology for next-generation genomic analysis, the SOLiD™ System, has been named the Life Science Innovation of the Year for 2008 by The Scientist, a leading scientific publication focused on the life science industry. In making the announcement of the first-ever Life Science Innovation of the Year Award, the publication recognized new technologies that represent a combination of invention, vision and utility during the past year.

Changing the Diagnostics Paradigm: Oxford NanoLabs' Next-Generation Analytical System Will Bring the Genetic Revolution to Modern Healthcare
Oxford NanoLabs' nanopore-based platform that offers rapid, early, cost-effective, highly sensitive, and accurate diagnosis at the point-of-care will be discussed by Dr. Spike WIllcocks in the Partnering Showcase of the Molecular Medicine Conference 2/27/07 in San Francisco. Oxford NanoLabs (ONL) currently has in development both a rapid influenza test and a blood-based Alzheimer's diagnostic. ONL's longer-term goal is to achieve $1,000 human-genome sequencing.